BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 24576034)

  • 1. Five important advances in hematopathology.
    Shi M; Xiao R; Woda BA; Yu H
    Arch Pathol Lab Med; 2014 Mar; 138(3):410-9. PubMed ID: 24576034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
    Orazi A
    Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular genetic biomarkers in myeloid malignancies.
    Matynia AP; Szankasi P; Shen W; Kelley TW
    Arch Pathol Lab Med; 2015 May; 139(5):594-601. PubMed ID: 25152312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic Testing in the Diagnosis and Biology of Myeloid Neoplasms (Excluding Acute Leukemias).
    Hasserjian RP; Kelley TW; Weinberg OK; Morgan EA; Fend F
    Am J Clin Pathol; 2019 Aug; 152(3):302-321. PubMed ID: 31263893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic markers for myeloid neoplasms: a comparative review of the literature and goals for future investigation.
    Juopperi TA; Bienzle D; Bernreuter DC; Vernau W; Thrall MA; McManus PM
    Vet Pathol; 2011 Jan; 48(1):182-97. PubMed ID: 21139142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Diagnostic molecular pathology of lymphatic and myeloid neoplasms].
    Klapper W; Kreipe H
    Pathologe; 2015 Mar; 36(2):164-70. PubMed ID: 25809654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
    Bock O
    Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current pathology practices in and barriers to MDS diagnosis.
    Glauser TA; Sagatys EM; Williamson JC; Burton BS; Berger C; Merwin P; Sugrue M; Bennett JM
    Leuk Res; 2013 Dec; 37(12):1656-61. PubMed ID: 24220584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis.
    Kremer M; Horn T; Dechow T; Tzankov A; Quintanilla-Martínez L; Fend F
    Leukemia; 2006 Jul; 20(7):1315-6. PubMed ID: 16617316
    [No Abstract]   [Full Text] [Related]  

  • 10. Focus on myeloproliferative diseases and myelodysplastic syndromes.
    Van Etten RA; Shannon KM
    Cancer Cell; 2004 Dec; 6(6):547-52. PubMed ID: 15607959
    [No Abstract]   [Full Text] [Related]  

  • 11. Myelodysplastic syndrome evolving into a myeloproliferative disorder: one disease or two?
    Verhoef GE; Demuynck H; Zachee P; Boogaerts MA
    Leukemia; 1994 Apr; 8(4):714-5. PubMed ID: 8152271
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to Kremer M et al., the JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis.
    Ohyashiki K; Ohyashiki JH
    Leukemia; 2006 Jul; 20(7):1297-8. PubMed ID: 16617315
    [No Abstract]   [Full Text] [Related]  

  • 13. New molecular insights in myelodysplastic and myeloproliferative disorders.
    Emanuel PD
    Clin Adv Hematol Oncol; 2005 Jun; 3(6):459-60. PubMed ID: 16167021
    [No Abstract]   [Full Text] [Related]  

  • 14. Pathology consultation on intermediate-to-large B-cell lymphomas.
    Montgomery ND; Fedoriw Y
    Am J Clin Pathol; 2014 Mar; 141(3):305-17. PubMed ID: 24515757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myeloid malignancies: myelodysplastic syndromes, myeloproliferative disorders, and acute myeloid leukemia.
    Wood BL
    Clin Lab Med; 2007 Sep; 27(3):551-75, vii. PubMed ID: 17658407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical applications of molecular haematology: flow cytometry in leukaemias and myelodysplastic syndromes.
    Dalal BI
    J Assoc Physicians India; 2007 Aug; 55():571-3. PubMed ID: 18019799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis.
    Machherndl-Spandl S; Sega W; Bösmüller H; Germing U; Gruber Ch; Nachtkamp K; Reinecke P; Sperr WR; Wimazal F; Müllauer L; Sotlar K; Horny HP; Tüchler H; Valent P; Krieger O
    Ann Hematol; 2014 Jan; 93(1):57-64. PubMed ID: 24241126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biologic abnormalities in the myelodysplastic syndromes and myeloproliferative disorders.
    Greenberg PL
    Nihon Ketsueki Gakkai Zasshi; 1986 Dec; 49(8):1509-27. PubMed ID: 3551435
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinicopathological features of unbalanced translocation Der(1;7)(q10;p10) in myeloid neoplasms.
    So CC; Ma ES; Wan TS; Yip SF; Chan LC
    Leuk Res; 2008 Jun; 32(6):1000-1. PubMed ID: 17980911
    [No Abstract]   [Full Text] [Related]  

  • 20. The implications of revised WHO classification (2008) of chronic myeloid neoplasms.
    Găman M; Vlădăreanu AM; Radesi S
    Rom J Intern Med; 2011; 49(1):25-30. PubMed ID: 22026249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.